Abstract
The carbonic anhydrase (CA) family has recently become an important target for the drug design of inhibitors with potential use as diagnostic and therapeutic tools. However, given the high degree of sequence and structure similarity among the different CA isoforms, no CA-directed drug developed so far has displayed selectivity for a specific isozyme. Since X-Ray crystallography is a very useful tool for the rational drug design of selective enzyme inhibitors, in recent years extensive research efforts have been devoted to the structural studies of all catalytically active α-CA isoforms, with the consequent resolution of the crystallographic structures of nearly all such enzyme isoforms. In this paper we review the progress that has recently been made in this field. In particular, we summarize the main structural features of hCA XIII and hCA IX, the most recently characterized human CA isoforms, and recapitulate how 3D structures of these enzymes, together with kinetic experiments, have been used either to deepen our knowledge on the structural features responsible of the catalytic properties of this protein family or to obtain important information for the rational drug design of inhibitors with better selectivity properties.
Keywords: Carbonic Anhydrase IX, Carbonic Anhydrase XIII, inhibitor, structure based drug design, crystal structure, carbonic anhydrase (CA), isozyme, X-Ray crystallography, 3D structures, ubiquitous metallo-enzymes, CA inhibitors (CAIs), diuretics, antiglaucoma, antiepileptics, submandibular gland, Cytosolic CA Isozymes, mutagenesis, HUMAN CA IX, transmembrane segment (TM), intracytoplasmic (IC) portion, N-terminal proteoglycan, disulfide bond, Mass spectrometry, hypoxic phenotype, anion exchangers (AEs), Na+/bicarbonate cotransporters (NBCs), apoptosis, tumor cells, anticonvulsants, spermatogenesis, Carbonic anhydrase, Human CA, Murine CA, Hypoxia inducible factor, Hypoxia response elements, Anion exchanger, Na+/bicarbonate cotransporter, Transmembrane, Intracytoplasmic, Proteoglycan-like domain
Current Pharmaceutical Design
Title: Recent Advances in Structural Studies of the Carbonic Anhydrase Family: The Crystal Structure of Human CA IX and CA XIII
Volume: 16 Issue: 29
Author(s): Claudiu T. Supuran, Anna Di Fiore, Vincenzo Alterio, Simona Maria Monti and Giuseppina De Simone
Affiliation:
Keywords: Carbonic Anhydrase IX, Carbonic Anhydrase XIII, inhibitor, structure based drug design, crystal structure, carbonic anhydrase (CA), isozyme, X-Ray crystallography, 3D structures, ubiquitous metallo-enzymes, CA inhibitors (CAIs), diuretics, antiglaucoma, antiepileptics, submandibular gland, Cytosolic CA Isozymes, mutagenesis, HUMAN CA IX, transmembrane segment (TM), intracytoplasmic (IC) portion, N-terminal proteoglycan, disulfide bond, Mass spectrometry, hypoxic phenotype, anion exchangers (AEs), Na+/bicarbonate cotransporters (NBCs), apoptosis, tumor cells, anticonvulsants, spermatogenesis, Carbonic anhydrase, Human CA, Murine CA, Hypoxia inducible factor, Hypoxia response elements, Anion exchanger, Na+/bicarbonate cotransporter, Transmembrane, Intracytoplasmic, Proteoglycan-like domain
Abstract: The carbonic anhydrase (CA) family has recently become an important target for the drug design of inhibitors with potential use as diagnostic and therapeutic tools. However, given the high degree of sequence and structure similarity among the different CA isoforms, no CA-directed drug developed so far has displayed selectivity for a specific isozyme. Since X-Ray crystallography is a very useful tool for the rational drug design of selective enzyme inhibitors, in recent years extensive research efforts have been devoted to the structural studies of all catalytically active α-CA isoforms, with the consequent resolution of the crystallographic structures of nearly all such enzyme isoforms. In this paper we review the progress that has recently been made in this field. In particular, we summarize the main structural features of hCA XIII and hCA IX, the most recently characterized human CA isoforms, and recapitulate how 3D structures of these enzymes, together with kinetic experiments, have been used either to deepen our knowledge on the structural features responsible of the catalytic properties of this protein family or to obtain important information for the rational drug design of inhibitors with better selectivity properties.
Export Options
About this article
Cite this article as:
T. Supuran Claudiu, Di Fiore Anna, Alterio Vincenzo, Maria Monti Simona and De Simone Giuseppina, Recent Advances in Structural Studies of the Carbonic Anhydrase Family: The Crystal Structure of Human CA IX and CA XIII, Current Pharmaceutical Design 2010; 16 (29) . https://dx.doi.org/10.2174/138161210793429841
DOI https://dx.doi.org/10.2174/138161210793429841 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Current Protein-based Anti-angiogenic Therapeutics
Mini-Reviews in Medicinal Chemistry Plasticity of T Cell Differentiation and Cytokine Signature: A Double-Edged Sword for Immune Responses
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Protein Kinase Homology Models: Recent Developments and Results
Current Medicinal Chemistry Studies of NVP-BEZ235 in Melanoma
Current Cancer Drug Targets Eupatilin Inhibits the Proliferation and Migration of Prostate Cancer Cells through Modulation of PTEN and NF-κB Signaling
Anti-Cancer Agents in Medicinal Chemistry Immunossupressant and Organ Transplantation: Immunophilins Targeting Agent and Alternative Therapies
Current Medicinal Chemistry Morphologic and Molecular Backgrounds for Personalized Management of Genito-Urinary Cancers: An Overview
Current Drug Targets Targeting Angiogenesis in Renal Cell Carcinoma
Current Cancer Drug Targets Potential Disease Targets for Drugs that Disrupt Protein - Protein Interactions of Grb2 and Crk Family Adaptors
Current Pharmaceutical Design The HOX Gene Network as a Potential Target for Cancer Therapy
Current Cancer Therapy Reviews Synthesis of 4-substituted-3-hydroxy-5-oxo-10-oxa-4-azatricyclo[5.2.1]dec- 3-yl Acetic Acid Ethyl Esters as Norcantharidin Analogues
Letters in Drug Design & Discovery Quinazolines as Apoptosis Inducers and Inhibitors: A Review of Patent Literature
Recent Patents on Anti-Cancer Drug Discovery Novel Agents, Combinations and Sequences for the Treatment of Advanced Renal Cell Carcinoma: When is the Revolution Coming?
Current Cancer Drug Targets Tissue Elasticity Bridges Cancer Stem Cells to the Tumor Microenvironment Through microRNAs: Implications for a “Watch-and-Wait” Approach to Cancer
Current Stem Cell Research & Therapy QSAR and Docking Studies of N-hydroxy Urea Derivatives as Flap Endonuclease-1 Inhibitors
Current Computer-Aided Drug Design Elucidation of Cellular Metabolism Via Metabolomics and Stable-Isotope Assisted Metabolomics
Current Pharmaceutical Biotechnology Molecular Mechanisms of Epigenetic Regulators as Activatable Targets in Cancer Theranostics
Current Medicinal Chemistry Jade-1: its structure, regulation and functions in the renal cancer.
Current Molecular Medicine Mitochondrial Biogenesis Inhibitors for Anticancer Therapy: A Review of Recent Patents
Recent Patents on Anti-Cancer Drug Discovery ATP Non-Competitive Ser/Thr Kinase Inhibitors as Potential Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry